{"id":553445,"date":"2025-08-25T20:24:45","date_gmt":"2025-08-25T20:24:45","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/553445\/diabetic-neuropathy-clinical-trials-companies-therapies-therapies-pipeline-analysis-serodus-novartis-curacle-co-ltd-sonnet-biotherapeutics-inc-teijin-america-inc-shanghai-pharmaceutic.html"},"modified":"2025-08-25T20:24:45","modified_gmt":"2025-08-25T20:24:45","slug":"diabetic-neuropathy-clinical-trials-companies-therapies-therapies-pipeline-analysis-serodus-novartis-curacle-co-ltd-sonnet-biotherapeutics-inc-teijin-america-inc-shanghai-pharmaceutic","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/553445\/diabetic-neuropathy-clinical-trials-companies-therapies-therapies-pipeline-analysis-serodus-novartis-curacle-co-ltd-sonnet-biotherapeutics-inc-teijin-america-inc-shanghai-pharmaceutic.html","title":{"rendered":"Diabetic Neuropathy Clinical Trials, Companies, Therapies, Therapies, Pipeline Analysis | Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceutic"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\">\n<div><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2025\/08\/1756110940.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Neuropathy Clinical Trials, Companies, Therapies, Therapies, Pipeline Analysis | Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceutic\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/08\/1756110940.jpg\" alt=\"Diabetic Neuropathy Clinical Trials, Companies, Therapies, Therapies, Pipeline Analysis | Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Inc., Teijin America, Inc., Shanghai Pharmaceutic\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px;border:0 solid !important\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Diabetic Neuropathy Clinical Trials<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic;padding:8px 0px\">DelveInsight\u2019s, \u201cDiabetic Neuropathy- Pipeline Insight, 2025,\u201d report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify\">According to DelveInsight, the Diabetic Neuropathy pipeline includes over 20 key companies actively developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.<\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Overview:<\/strong><\/p>\n<p style=\"text-align: justify\">Diabetic neuropathy is a type of nerve damage that occurs in individuals with diabetes, particularly those with long-term poor blood sugar control. It mainly affects the peripheral nerves, which control sensation and movement in the limbs. Diabetic neuropathy can manifest in several forms, including peripheral neuropathy (impacting hands and feet), autonomic neuropathy (affecting internal organs), proximal neuropathy (causing pain in the thighs, hips, or buttocks), and focal neuropathy (targeting a specific nerve).<\/p>\n<p style=\"text-align: justify\">Symptoms vary depending on the type and extent of nerve damage. Peripheral neuropathy often presents as tingling, numbness, or pain in the extremities, which may worsen over time, potentially leading to loss of sensation and motor difficulties. Autonomic neuropathy can cause digestive issues, urinary problems, and cardiovascular complications. Proximal neuropathy typically causes pain in the thighs, hips, or buttocks, whereas focal neuropathy results in sudden, localized pain or weakness in a particular nerve.<\/p>\n<p style=\"text-align: justify\"><strong>Request for a detailed insights report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Diabetic Neuropathy pipeline insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&#8220;Diabetic Neuropathy Pipeline Insight 2025&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetic Neuropathy Therapeutics Market.<\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Diabetic Neuropathy Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">DelveInsight&rsquo;s Diabetic Neuropathy pipeline report highlights a vibrant landscape, featuring over 20 active companies developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.<\/p>\n<\/li>\n<li>\n<p>Leading companies, including Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Teijin America, Shanghai Pharmaceuticals, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma, Sunshine Lake Pharma, Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others, are actively evaluating novel therapies to enhance the management of diabetic neuropathy.<\/p>\n<\/li>\n<li>\n<p>Notable pipeline candidates in various stages of development include SER 150, LMB-763, CU01, among others.<\/p>\n<\/li>\n<li>\n<p>In January 2024, Neuralace Medical received FDA clearance for Axon Therapy, a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment for chronic painful diabetic neuropathy (PDN). This therapy delivers painless magnetic pulses in 13.5-minute sessions, representing a novel approach to pain management. Clinical evaluation through a double-blind, multicenter randomized controlled trial demonstrated a 72.3% responder rate and a 57.6% average reduction in pain scores at 30 days, with responder rates rising to 81.4% in the treatment group by 90 days.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The report provides insights into: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The report provides detailed insights into the key companies that are developing therapies in the Diabetic Neuropathy Market.<\/p>\n<\/li>\n<li>\n<p>The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Neuropathy treatment.<\/p>\n<\/li>\n<li>\n<p>It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetic Neuropathy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Download our free sample page report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Diabetic Neuropathy pipeline insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>SER 150: Serodus<\/p>\n<\/li>\n<li>\n<p>LMB-763: Novartis<\/p>\n<\/li>\n<li>\n<p>CU01: Curacle Co., Ltd<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Companies<\/strong><\/p>\n<p style=\"text-align: justify\">Over 20 leading companies are actively working on therapies for diabetic neuropathy, with Serodus having a candidate in the most advanced stage, currently progressing through Phase II\/III clinical trials.<\/p>\n<p style=\"text-align: justify\"><strong>DelveInsight&rsquo;s report covers around 25+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetic Neuropathy Therapies and Key Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Diabetic Neuropathy Clinical Trials and advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Diabetic Neuropathy Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Diabetic Neuropathy Assessment by Product Type<\/p>\n<p style=\"text-align: justify\">&bull; Diabetic Neuropathy By Stage<\/p>\n<p style=\"text-align: justify\">&bull; Diabetic Neuropathy Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify\">&bull; Diabetic Neuropathy Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify\"><strong>Download Diabetic Neuropathy Sample report to know in detail about the Diabetic Neuropathy treatment market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Diabetic Neuropathy Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify\">1. Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Diabetic Neuropathy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify\">4. Diabetic Neuropathy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify\">6. Diabetic Neuropathy Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify\">7. Diabetic Neuropathy Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify\">10. Inactive Products<\/p>\n<p style=\"text-align: justify\">11. Dormant Products<\/p>\n<p style=\"text-align: justify\">12. Diabetic Neuropathy Discontinued Products<\/p>\n<p style=\"text-align: justify\">13. Diabetic Neuropathy Product Profiles<\/p>\n<p style=\"text-align: justify\">14. Diabetic Neuropathy Key Companies<\/p>\n<p style=\"text-align: justify\">15. Diabetic Neuropathy Key Products<\/p>\n<p style=\"text-align: justify\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify\">17. Diabetic Neuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify\">18. Diabetic Neuropathy Future Perspectives<\/p>\n<p style=\"text-align: justify\">19. Diabetic Neuropathy Analyst Review<\/p>\n<p style=\"text-align: justify\">20. Appendix<\/p>\n<p style=\"text-align: justify\">21. Report Methodology<\/p>\n<p style=\"text-align: justify\"><strong>Request the Sample PDF to Get Detailed Insights About the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-neuropathy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Diabetic Neuropathy Pipeline Reports Offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-neuropathy-clinical-trials-companies-therapies-therapies-pipeline-analysis-serodus-novartis-curacle-co-ltd-sonnet-biotherapeutics-inc-teijin-america-inc-shanghai-pharmaceutic\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-neuropathy-clinical-trials-companies-therapies-therapies-pipeline-analysis-serodus-novartis-curacle-co-ltd-sonnet-biotherapeutics-inc-teijin-america-inc-shanghai-pharmaceutic\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetic Neuropathy Clinical Trials DelveInsight\u2019s, \u201cDiabetic Neuropathy- Pipeline Insight, 2025,\u201d report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/553445"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=553445"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/553445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=553445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=553445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=553445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}